Continuous-infusion Ifosfamide and Doxorubicin Combination as Second-Line Chemotherapy for Recurrent or Refractory Osteosarcoma Patients in China: a Retrospective Study

Huang, Yu-Jing; He, Ai-Na; Sun, Yuan-Jue; Shen, Zan; Min, Da-Liu; Yao, Yang

추천

검색

자료유형: 학술저널

저자정보: Huang, Yu-Jing (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) He, Ai-Na (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) Sun, Yuan-Jue (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) Shen, Zan (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) Min, Da-Liu (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) Yao, Yang (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제6호

발행연도: 2015.1

수록면: 2,391 - 2,395 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objective: The aim of this retrospective study was to evaluate the feasibility and efficacy of response to continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for patients with recurrent or refractory osteosarcoma. Materials and Methods: Eighteen recurrent or refractory osteosarcoma patients who were treated with continuous-infusion ifosfamide and doxorubicin combination between May 1999 and April 2011 were included in the analysis. Ifosfamide at $12g/m^2$ was administered by intravenous continuous infusion over 3 days, and doxorubicin $60mg/m^2$ was administered as an intravenous bolus injection on day 1. The combination therapy was repeated every 3 weeks. Treatment was continued until evidence of disease progression or unacceptable toxicity. Results: The patients (ages 7-53 years) received a total of 42 cycles of chemotherapy (median: 2 courses; range: 2-5 courses). The overall response rate was 0% and the disease control rate was 22.3%, with four patients having stable disease. The median time to progression and overall survival time were 2 months (range: 2-5 months) and 9 months (range: 3-29 months), respectively. Major severe toxicities were leucopenia 7 (38.9%), nausea and vomiting 3 (16.7%) and alopecia 9 (50%). There were no treatment-related deaths. Conclusions: In our experience, continuous-infusion ifosfamide and doxorubicin combination therapy at this dosage and schedule was found to be well tolerated and moderate effective, which could be considered as salvage therapy for patients with recurrent or refractory osteosarcoma. Further assessment is necessary to confirm the safety and efficacy of this treatment.

#Continuous-infusion #ifosfamide #doxorubicin #salvage chemotherapy #osteosarcoma

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!